455 related articles for article (PubMed ID: 37321060)
1. Nox4 as a novel therapeutic target for diabetic vascular complications.
Wang D; Li J; Luo G; Zhou J; Wang N; Wang S; Zhao R; Cao X; Ma Y; Liu G; Hao L
Redox Biol; 2023 Aug; 64():102781. PubMed ID: 37321060
[TBL] [Abstract][Full Text] [Related]
2. Interplay between RNA-binding protein HuR and Nox4 as a novel therapeutic target in diabetic kidney disease.
Shi Q; Lee DY; Féliers D; Abboud HE; Bhat MA; Gorin Y
Mol Metab; 2020 Jun; 36():100968. PubMed ID: 32240965
[TBL] [Abstract][Full Text] [Related]
3. Nox4 and diabetic nephropathy: with a friend like this, who needs enemies?
Gorin Y; Block K
Free Radic Biol Med; 2013 Aug; 61():130-42. PubMed ID: 23528476
[TBL] [Abstract][Full Text] [Related]
4. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy.
Sedeek M; Callera G; Montezano A; Gutsol A; Heitz F; Szyndralewiez C; Page P; Kennedy CR; Burns KD; Touyz RM; Hébert RL
Am J Physiol Renal Physiol; 2010 Dec; 299(6):F1348-58. PubMed ID: 20630933
[TBL] [Abstract][Full Text] [Related]
5. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.
Jha JC; Gray SP; Barit D; Okabe J; El-Osta A; Namikoshi T; Thallas-Bonke V; Wingler K; Szyndralewiez C; Heitz F; Touyz RM; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
J Am Soc Nephrol; 2014 Jun; 25(6):1237-54. PubMed ID: 24511132
[TBL] [Abstract][Full Text] [Related]
6. Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity.
Muñoz M; López-Oliva ME; Rodríguez C; Martínez MP; Sáenz-Medina J; Sánchez A; Climent B; Benedito S; García-Sacristán A; Rivera L; Hernández M; Prieto D
Redox Biol; 2020 Jan; 28():101330. PubMed ID: 31563085
[TBL] [Abstract][Full Text] [Related]
7. A NOX4/TRPC6 Pathway in Podocyte Calcium Regulation and Renal Damage in Diabetic Kidney Disease.
Ilatovskaya DV; Blass G; Palygin O; Levchenko V; Pavlov TS; Grzybowski MN; Winsor K; Shuyskiy LS; Geurts AM; Cowley AW; Birnbaumer L; Staruschenko A
J Am Soc Nephrol; 2018 Jul; 29(7):1917-1927. PubMed ID: 29793963
[No Abstract] [Full Text] [Related]
8. Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease.
Gorin Y; Wauquier F
Mol Cells; 2015 Apr; 38(4):285-96. PubMed ID: 25824546
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol inhibits renal interstitial fibrosis in diabetic nephropathy by regulating AMPK/NOX4/ROS pathway.
He T; Xiong J; Nie L; Yu Y; Guan X; Xu X; Xiao T; Yang K; Liu L; Zhang D; Huang Y; Zhang J; Wang J; Sharma K; Zhao J
J Mol Med (Berl); 2016 Dec; 94(12):1359-1371. PubMed ID: 27488452
[TBL] [Abstract][Full Text] [Related]
10. Linking RAGE and Nox in diabetic micro- and macrovascular complications.
Koulis C; Watson AMD; Gray SP; Jandeleit-Dahm KA
Diabetes Metab; 2015 Sep; 41(4):272-281. PubMed ID: 26323666
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4.
Li J; Wang JJ; Yu Q; Chen K; Mahadev K; Zhang SX
Diabetes; 2010 Jun; 59(6):1528-38. PubMed ID: 20332345
[TBL] [Abstract][Full Text] [Related]
12. Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes.
Maalouf RM; Eid AA; Gorin YC; Block K; Escobar GP; Bailey S; Abboud HE
Am J Physiol Cell Physiol; 2012 Feb; 302(3):C597-604. PubMed ID: 22031600
[TBL] [Abstract][Full Text] [Related]
13. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
[TBL] [Abstract][Full Text] [Related]
14. Early Growth Response 1 (Egr1) Is a Transcriptional Activator of NOX4 in Oxidative Stress of Diabetic Kidney Disease.
Hu F; Xue M; Li Y; Jia YJ; Zheng ZJ; Yang YL; Guan MP; Sun L; Xue YM
J Diabetes Res; 2018; 2018():3405695. PubMed ID: 29854821
[TBL] [Abstract][Full Text] [Related]
15. Nox (NADPH Oxidase) 1, Nox4, and Nox5 Promote Vascular Permeability and Neovascularization in Retinopathy.
Deliyanti D; Alrashdi SF; Touyz RM; Kennedy CR; Jha JC; Cooper ME; Jandeleit-Dahm KA; Wilkinson-Berka JL
Hypertension; 2020 Apr; 75(4):1091-1101. PubMed ID: 32114846
[TBL] [Abstract][Full Text] [Related]
16. Sustained Upregulation of Endothelial Nox4 Mediates Retinal Vascular Pathology in Type 1 Diabetes.
Tang X; Wang J; Abboud HE; Chen Y; Wang JJ; Zhang SX
Diabetes; 2023 Jan; 72(1):112-125. PubMed ID: 36321974
[TBL] [Abstract][Full Text] [Related]
17. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.
Gorin Y; Cavaglieri RC; Khazim K; Lee DY; Bruno F; Thakur S; Fanti P; Szyndralewiez C; Barnes JL; Block K; Abboud HE
Am J Physiol Renal Physiol; 2015 Jun; 308(11):F1276-87. PubMed ID: 25656366
[TBL] [Abstract][Full Text] [Related]
18. NADPH oxidase: A membrane-bound enzyme and its inhibitors in diabetic complications.
Laddha AP; Kulkarni YA
Eur J Pharmacol; 2020 Aug; 881():173206. PubMed ID: 32442539
[TBL] [Abstract][Full Text] [Related]
19. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney.
Gorin Y; Block K; Hernandez J; Bhandari B; Wagner B; Barnes JL; Abboud HE
J Biol Chem; 2005 Nov; 280(47):39616-26. PubMed ID: 16135519
[TBL] [Abstract][Full Text] [Related]
20. Effects of Nox4 upregulation on PECAM-1 expression in a mouse model of diabetic retinopathy.
Wang J; Lai DA; Wang JJ; Zhang SX
PLoS One; 2024; 19(5):e0303010. PubMed ID: 38748682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
